Zacks: Brokerages Expect Nightstar Therapeutics (NITE) to Announce -$0.39 Earnings Per Share

Equities research analysts forecast that Nightstar Therapeutics (NASDAQ:NITE) will report earnings of ($0.39) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Nightstar Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.29) and the lowest estimate coming in at ($0.48). The company is expected to report its next quarterly earnings results on Tuesday, July 3rd.

According to Zacks, analysts expect that Nightstar Therapeutics will report full-year earnings of ($1.83) per share for the current fiscal year, with EPS estimates ranging from ($2.37) to ($1.16). For the next financial year, analysts expect that the business will report earnings of ($1.65) per share, with EPS estimates ranging from ($1.98) to ($1.22). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Nightstar Therapeutics.

A number of research analysts have weighed in on NITE shares. Zacks Investment Research downgraded Nightstar Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, April 7th. Mizuho started coverage on Nightstar Therapeutics in a research report on Tuesday, February 27th. They issued a “buy” rating and a $20.00 price target on the stock. Wedbush reissued an “outperform” rating and issued a $31.00 price target on shares of Nightstar Therapeutics in a research report on Thursday, April 5th. Finally, ValuEngine raised Nightstar Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company’s stock. Nightstar Therapeutics currently has an average rating of “Buy” and an average target price of $28.50.

A hedge fund recently bought a new stake in Nightstar Therapeutics stock. Millennium Management LLC purchased a new position in Nightstar Therapeutics (NASDAQ:NITE) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 35,308 shares of the company’s stock, valued at approximately $507,000. Millennium Management LLC owned approximately 0.13% of Nightstar Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 29.19% of the company’s stock.

Shares of Nightstar Therapeutics traded down $0.20, reaching $13.80, during midday trading on Friday, reports. 19,256 shares of the stock were exchanged, compared to its average volume of 10,333. Nightstar Therapeutics has a 1 year low of $10.01 and a 1 year high of $24.93. The company has a market capitalization of $387.78 million and a price-to-earnings ratio of -8.47.

About Nightstar Therapeutics

Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate includes NSR-REP1, a candidate that has completed Phase 1/2 clinical trial for the treatment of patients with choroideremia.

Get a free copy of the Zacks research report on Nightstar Therapeutics (NITE)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Nightstar Therapeutics (NASDAQ:NITE)

Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply